Satellite Symposia

Sponsored Symposia Overview

Thursday, June 23, 2011

12:00 pm – 1:00 pm

Sponsored Symposia

Treatment Strategies on the Front End Improve Heart Failure

Speaker(s):

Shawn Merhaut, RN, MSN, ACNP-BC

Program Overview:

• The participant will be able to describe how treatment protocols in the pre-hospital setting impact patient outcomes.
• The participant will be able to identify two treatment protocols in ED that impact patient outcomes.
• The participant will be able to describe how the Society of Chest Pain Center Heart Failure Accreditation provides a road map for improving patient outcomes.

Generously supported by Society for Chest Pain Centers

1:00 pm – 2:00 pm

Concurrent Sponsored Symposia

Epidemiology, Pathophysiology and Therapeutic Targets in Stable Ischemic Heart Disease

Speaker(s):

Rebecca Angerstein, MA, MSN, CCRN, FAHA

Program Overview:

This activity will discuss the epidemiologic trends as well as the health and economic burden of stable ischemic heart disease (SIHD), focusing on chronic stable angina. In addition, discussion will include important pathophysiologic factors in chronic stable angina and their implications with regard to traditional and new therapeutic targets.

Generously supported by Gilead

Vitamins, Fish Oil and Heart Failure

Speaker(s):

James Hill, MD, MS, FACC

Program Overview:

This lecture will present an overview of what is known about vitamin deficiency in patient with heart failure. Specifically topics to be discussed will be the effect of heart failure therapy on micronutrient levels, data on the prevalence of various vitamin deficiencies and the effects of treatment on outcome. The major emphasis will be on thiamine, vitamin D and fish oils.

Learning objectives:

• Understand the prevalence of vitamin deficiency in patients with heart failure
• Clarify the effects of treatment with fish oils on outcome in heart failure
• Review literature on the contribution of vitamin D to cardiac disease

Generously supported by Corceuticals

Heart Failure + Sleep Apnea: Best Practices in Patient Adherence

Speaker(s):

Scott Alberts, RRT

Program Overview:

Brief overview of the clinical connection between heart failure and sleep apnea supported by clinical studies
Heart Failure nurse and HME role in supporting patient adherence
Best practices in solving patient adherence challenges
Identify key indicators of a quality service provider
Ask the expert – Question and answer session

Generously supported by Philips Respironics and ResMed

Friday, June 24, 2011

7:00 am – 8:00 am

Concurrent Sponsored Symposia

Hemodynamics and the Role of Pressure-Guided Therapy in Heart Failure Management

Speaker(s):

Ayesha Hasan, MD
Laura Yamokoski, BSN, RN, MA, CCRC
Mary Louise Osevala, RN, MSN, ANP-BC

Program Overview:

1. Describe the current methods of predicting acute decompensated heart failure (ADHF)
2. Understand the benefits and value of pressure-guided therapy in Heart Failure Management
3. Understand the future goals of integrating pressure-guided therapy in the clinic workflow

Generously supported by CardioMEMS

Expanded Indications and Early Intervention with CRT Symposium

Speaker(s):

Vera Barton-Caro, RN, MSN, FNP-BC
Marie Galvao, RN, MSN, ANP-BC
Lisa Rathman, RN

Program Overview:

1. Be able to identify HF patients who would likely benefit from cardiac resynchronization therapy;
2. Understand the expanded indications for cardiac resynchronization therapy;
3. Understand the benefits of early intervention with cardiac resynchronization therapy and;
4. Understand the benefit of remote follow-up with CRT devices using device, EP and HF diagnostics

Generously supported by Boston Scientific

6:00 pm – 7:00 pm

Sponsored Symposia

Sudden Cardiac Arrest Risk Screening in Heart Failure – Using the WCD

Speaker(s):

Robin J. Trupp, PhD, ARNP-BC

Program Overview:

This program is intended to educate HF clinicians on the risk of Sudden Cardiac Arrest in Heart Failure patients. Risk Stratification and Screening strategies to identify the highest risk patients will be discussed in addition to treatment strategies, including the use of the LifeVest wearable Cardioverter defibrillator to protect patients at risk during medical optimization and while long-term treatment decisions are being made.

Learning Objectives:

After attending this education program, attendees should be able to:

• Apply clinical evidence and guidelines to identify patients at risk for SCA
• Recognize how SCA screening protocols can be helpful in screening patients at risk
• Understand how the use of the LifeVest Wearable Cardioverter Defibrillator can assist in protecting patients from SCA during medical optimization and while clinician assessment of long term risk is ongoing.

Generously supported by Zoll

Saturday, June 25, 2011

7:00 am – 8:00 am

Concurrent Sponsored Symposia

Leveraging Implantable Device Diagnostics in the Management of Heart Failure

Speaker(s):

Lynn Broesch, RN

Program Overview:

The purpose of this Medtronic sponsored educational program is to educate clinicians on the use of device based diagnostics in the treatment of heart failure patients and also how to implement these tools into clinic workflow.

Session Objectives:

At the conclusion of this program, participants will be able to:

• Discuss the clinical and economic implications of decompensated HF and the challenges related to managing these patients.
• Demonstrate an understanding of the literature relative to device based heart failure diagnostics, focusing attention on recent risk stratification evidence.
• Outline how device diagnostics can be incorporated into the routine in-office and remote management of patients.

Generously supported by Medtronic

Recognition and Treatment of HypoNatremia in Heart Failure

Speaker(s):

Mary Louise Osevala, RN, MSN, ANP-BC
Douglas D. Schocken, MD

Program Overview:

Hyponatremia is the most common electrolyte disorder of hospitalized patients,1 and studies in heart failure (HF) report a prevalence of up to 27%.2,3 In patients with HF, decreasing cardiac function and a reduced volume of circulating blood may result in increased secretion of vasopressin. Vasopressin-mediated inhibition of renal free water excretion leads to increased vascular volume, reduction of serum [Na+], and edema.2 Since water homeostasis is tightly regulated by vasopressin, inhibition of this hormone in the renal tubule can help to stimulate free water clearance and raise serum [Na+].4-6 Treatments that target the pathophysiology of hyponatremia may help to improve its management in HF patients.

Generously supported by Otsuka